SDHB and CDK1 protein expression in metastatic pheochromocytoma and paraganglioma

Endocrine Oncology · Published 2026-08-05 · DOI 10.1530/eo-26-0035

Free full text

Authors (5)

Lisa Gunnesson, Sinan Karakaya, Sofie Mohlin, Andreas Muth, Erik Elias

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Gunnesson, L., Karakaya, S., Mohlin, S., et al. (2026). SDHB and CDK1 protein expression in metastatic pheochromocytoma and paraganglioma. Endocrine Oncology. https://doi.org/10.1530/eo-26-0035

Related articles

• HbA1c screening in patients with early breast cancer receiving endocrine therapy · Endocrine Oncology · 2025 · Same journal
• Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas · Endocrine Oncology · 2025 · Same journal
• Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE · Endocrine Oncology · 2025 · Same journal
• 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence · Endocrine Oncology · 2025 · Same journal
• Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes · Endocrine Oncology · 2025 · Same journal
• To screen or not to screen: complexity of SDHA mutation management · Endocrine Oncology · 2026 · Same journal
• Adrenal crisis due to pembrolizumab-induced hypophysitis in a patient with triple-negative breast cancer · Endocrine Oncology · 2025 · Same journal
• Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer · Endocrine Oncology · 2025 · Same journal
• Patient-reported symptom and urgent healthcare use in neuroendocrine tumors · Endocrine Oncology · 2026 · Same journal
• Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute · Endocrine Oncology · 2025 · Same journal